S&P 500 7,799 +1.15% Nasdaq 26,803 +1.73% Dow Jones 53,840 -0.08% FTSE 100 10,773 -0.88% DAX 26,300 +0.61% Nikkei 225 68,718 +4.74% Hang Seng 25,156 -1.99% WTI Crude 82.13 +0.00% Gold 4,385 +0.54% US 10-Year Treasury Yield 4.641 -0.41% S&P 500 7,799 +1.15% Nasdaq 26,803 +1.73% Dow Jones 53,840 -0.08% FTSE 100 10,773 -0.88% DAX 26,300 +0.61% Nikkei 225 68,718 +4.74% Hang Seng 25,156 -1.99% WTI Crude 82.13 +0.00% Gold 4,385 +0.54% US 10-Year Treasury Yield 4.641 -0.41%

LATEST

Molbio Diagnostics IPO listing in focus: GMP signals nearly 20% listing pop ahead of debut on Monday●Page Industries faces volume-margin tightrope after soft Q1●BTG Pactual Raises Its Méliuz Stake to 10.51% in New Filing●Cosan Puts Its São Luís Port Terminal Up for Sale to Cut Debt●Chile’s Competition Court Fines Metrogas About US$3.6 Million●CSN Weighs Selling a Minority Stake in Its Logistics Business●US long-term borrowing costs hit 25-year high, as inflation fears hit bond sale – business live●Bitcoin holders Strategy and Metaplanet face stock-index exclusion under MSCI’s new proposal●Molbio Diagnostics IPO listing in focus: GMP signals nearly 20% listing pop ahead of debut on Monday●Page Industries faces volume-margin tightrope after soft Q1●BTG Pactual Raises Its Méliuz Stake to 10.51% in New Filing●Cosan Puts Its São Luís Port Terminal Up for Sale to Cut Debt●Chile’s Competition Court Fines Metrogas About US$3.6 Million●CSN Weighs Selling a Minority Stake in Its Logistics Business●US long-term borrowing costs hit 25-year high, as inflation fears hit bond sale – business live●Bitcoin holders Strategy and Metaplanet face stock-index exclusion under MSCI’s new proposal●

Asia

Galaxy Surfactants shares hit 20% upper circuit as Q1 profit more than doubles YoY to Rs 166 crore

Markets-Economic Times · 1h ago · 🇮🇳 India

Galaxy Surfactants shares hit 20% upper circuit as Q1 profit more than doubles YoY to Rs 166 crore

Galaxy Surfactants shares hit a 20% upper circuit after the company reported a 109% year-on-year jump in Q1FY27 net profit to Rs 165.9 crore. Revenue rose 38.5%, while EBITDA surged 87% to a record Rs 252.5 crore, supported by stronger volumes, product mix and speciality care demand.

Read the full story at Markets-Economic Times →

More Asia

Molbio Diagnostics IPO listing in focus: GMP signals nearly 20% listing pop ahead of debut on Monday

mint - markets · 9m ago

Page Industries faces volume-margin tightrope after soft Q1

mint - markets · 9m ago

Shein eyes a valuation rivalling H&M. Will the market buy it?

Business - South China Morning Post · 30m ago

Small-cap engineering stock dips after giving a technical breakout. Should you buy?

mint - markets · 31m ago